Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.65 |
| ▸ | NQO2 | P16083 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998772 | 1.00 | ESR1 (0.65) | ESR1ESR2NQO2ABCG2LTA4H | |
| SCHEMBL28618985 | 0.96 | ESR1 (0.60) | ESR1ESR2NQO2ABCG2LTA4H | |
| SCHEMBL20156660 | 0.94 | ALDH1A1 (0.54) | ESR1ESR2NQO2ABCG2ALDH1A1 | |
| SCHEMBL11332814 | 0.92 | ALDH1A1 (0.52) | ESR1ESR2NQO2LTA4HNR5A1 | |
| SCHEMBL11332817 | 0.92 | ALDH1A1 (0.52) | ESR1ESR2NQO2LTA4HNR5A1 | |
| SCHEMBL11659439 | 0.90 | TP53 (0.52) | ESR1ESR2NQO2NR5A1ALDH1A1 | |
| SCHEMBL11656786 | 0.90 | TP53 (0.52) | ESR1ESR2NQO2NR5A1ALDH1A1 | |
| SCHEMBL11660429 | 0.90 | TP53 (0.52) | ESR1ESR2NQO2NR5A1ALDH1A1 | |
| SCHEMBL11658644 | 0.87 | NQO2 (0.59) | ESR1ESR2NQO2ALDH1A1HPGD | |
| SCHEMBL10635627 | 0.87 | TP53 (0.49) | ESR1ESR2NQO2NR5A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | claimed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | claimed |
| CN-1744892-A | Breast cancer resistance protein (BCRP) inhibitor | YAKULT HONSHA KK (JP) | 2006-03-08 | — | — | CN | claimed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | claimed |
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1744892-A | Breast cancer resistance protein (BCRP) inhibitor | YAKULT HONSHA KK (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | ESR1 413/4885ESR2 454/4885NQO2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.